These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15841507)

  • 1. Spanish wishful thinking towards biotech.
    Sheridan C
    Nat Biotechnol; 2005 Mar; 23(3):385. PubMed ID: 15841507
    [No Abstract]   [Full Text] [Related]  

  • 2. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 3. Selling out.
    Martin JF
    Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
    [No Abstract]   [Full Text] [Related]  

  • 4. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 6. Can Europe accelerate out of trouble?
    Nat Biotechnol; 2006 Sep; 24(9):1040. PubMed ID: 16964194
    [No Abstract]   [Full Text] [Related]  

  • 7. Shareholders flex their muscles.
    Thiel K
    Nat Biotechnol; 2008 Jan; 26(1):19-21. PubMed ID: 18183007
    [No Abstract]   [Full Text] [Related]  

  • 8. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 9. Convincing a venture capitalist to invest in your idea.
    Dooley JF; Dooley JF
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE45-8. PubMed ID: 12874980
    [No Abstract]   [Full Text] [Related]  

  • 10. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 11. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 12. Virtual reality: the promise and pitfalls of going virtual.
    Broderson H
    Nat Biotechnol; 2005 Oct; 23(10):1205-7. PubMed ID: 16302295
    [No Abstract]   [Full Text] [Related]  

  • 13. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 14. Genentech makes its first-ever acquisition.
    Hollmer M
    Nat Biotechnol; 2007 Jan; 25(1):4-5. PubMed ID: 17211375
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotechnology in South Africa.
    Cloete TE; Nel LH; Theron J
    Trends Biotechnol; 2006 Dec; 24(12):557-62. PubMed ID: 17070947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese biotech: the need for innovation and higher standards.
    Wong GH
    Nat Biotechnol; 2006 Feb; 24(2):221-2. PubMed ID: 16465169
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 18. France to focus on a few biotech clusters.
    Balcon E
    Nat Biotechnol; 2004 Sep; 22(9):1063-4. PubMed ID: 15340457
    [No Abstract]   [Full Text] [Related]  

  • 19. Marketing biotechnology with a Gallic flair.
    Jouanneau AC
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
    [No Abstract]   [Full Text] [Related]  

  • 20. Where to float?
    Moran N
    Nat Biotechnol; 2008 Oct; 26(10):1063-6. PubMed ID: 18924252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.